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Abstract
High affinity binding of dihydrotestosterone (DHT) to the androgen receptor (AR) initiates
androgen-dependent gene activation required for normal male sex development in utero, and
contributes to prostate cancer development and progression in men. Under normal physiological
conditions, DHT is synthesized predominantly by 5α-reduction of testosterone, the major
circulating androgen produced by the testis. During androgen deprivation therapy, intratumoral
androgen production is sufficient for AR activation and prostate cancer growth even though
circulating testicular androgen levels are low. Recent studies indicate that the metabolism of 5α-
androstane-3α,17β-diol by 17β-hydroxysteroid dehydrogenase 6 in benign prostate and prostate
cancer cells is a major biosynthetic pathway for intratumoral synthesis of DHT that binds AR and
initiates transactivation to promote prostate cancer growth during androgen deprivation therapy.
Drugs that target the so-called backdoor pathway of DHT synthesis provide an opportunity to
enhance clinical response to LHRH agonists or antagonists, AR antagonists, inhibitors of 5α-
reductase enzymes, finasteride or dutasteride, and steroid metabolism enzyme inhibitors,
ketoconazole or the recently available abiraterone acetate.
BACKGROUND
Normal male sex development and growth depend on high affinity binding of
dihydrotestosterone (DHT, 5α-androstan-17β-ol-3-one), the 5α-reduced product of
testosterone (T, 4-androsten-17β-ol-3-one), to the androgen receptor (AR), an essential
ligand-dependent transcription factor that regulates androgen-dependent gene transcription.
AR binds T and DHT with similar high equilibrium binding affinity (equilibrium
dissociation constant, Kd ~0.3 nM) (1), and T and DHT are the only naturally occurring
steroids that activate wild-type AR. AR is not activated directly by binding either 5α-
androstane-3α,17β-diol (androstanediol) or dehydroepiandrosterone (DHEA). Androgen
specificity for AR transcriptional signaling is achieved through the highly structured AR
ligand binding domain, and the selective ability of T and DHT to induce the AR NH2- and
carboxyl-terminal interaction that stabilizes AR and increases transcriptional activity (2, 3).
The well established differences in potency between T and DHT (4) result not from
differences in AR equilibrium androgen binding affinity, but from the greater
hydrophobicity of DHT that strengthens human AR intermolecular interactions, slows the
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dissociation rate of bound androgen, and stabilizes the ligand-bound AR to render DHT a
more active androgen than T (1, 5).
The requirement for DHT in normal prostate growth and development of the external
genitalia is demonstrated by the 5α-reductase syndrome. An inactivating mutation in the
type 2 isoform of the 5α-reductase enzyme that converts T to DHT results in a small prostate
gland and predominantly female or ambiguous external phenotype in affected newborn
males with 46XY chromosomes (6). The 5α-reductase syndrome provides physiological
evidence that circulating DHT arises from T, and that DHT is required for normal male sex
development. On the other hand, untreated 5α-reductase syndrome patients begin to virilize
at puberty. This suggests that the pubertal rise in T compensates for low DHT, or that a
pubertal rise in the type 1 isoform of 5α-reductase (7, 8) acts on other steroid precursors
such as 17α-hydroxyprogesterone to form 5α-pregnane-17α-ol-3,20-dione and eventually
DHT (Fig. 1).
AR is a critical transcriptional regulator required to establish the normal male sex
phenotype, and for the development and progression of prostate cancer (9–11). Regression
of prostate cancer after medical or surgical androgen deprivation therapy is followed
invariably by the development of castration-recurrent or castration-resistant prostate cancer
(CRPC), which demonstrates an initial reliance of prostate cancer growth on AR mediated
gene transcription in response to DHT. AR levels are often increased in CRPC consistent
with the continued expression of AR-stimulated genes (12). Additional growth stimulating
mechanisms in CRPC include increased levels of AR coregulators, transcription factors and/
or phosphorylation that render AR more sensitive to much lower levels of intratumoral
androgen, and growth factor and cytokine activation independent of androgen. AR
mutations, though rare in prostate cancer, can decrease specificity of AR steroid binding that
results in a more promiscuous transcriptional activator that responds to a broader range of
ligands (13–16).
Recent studies highlight the potential importance of intratumoral androgen biosynthesis in
prostate cancer (17–22). Mass spectrometry measurements of CRPC tissue extracts indicated
~2 nM DHT sufficient to activate AR (17, 18). In agreement with these findings, finasteride,
a 5α-reductase type 2 inhibitor, or dutasteride, a dual 5α-reductase types 1 and 2 inhibitor
(Fig. 1), were ineffective in preventing prostate cancer development (23, 24) or in treating
aggressive prostate cancer (25, 26). One interpretation of these clinical studies is that
alternative androgen biosynthetic pathways provide sufficient DHT to activate AR in the
abnormal cellular environment of prostate cancer. CRPC also is characterized by increased
expression of a family of related p160 coactivators, named for their approximate 160 kDa
molecular weight, and other coregulators that enhance AR sensitivity to low level androgens
(27, 28). One example is the AR coregulator, melanoma antigen-A11 (MAGE-11), whose
mRNA levels increase in ~30% of CRPC. In one patient with rapidly progressing prostate
cancer, MAGE-11 mRNA levels were three orders of magnitude above the normal range,
whereas AR mRNA in this patient sample was undetectable using quantitative reverse
transcription-polymerase chain reaction (RT-PCR) (28). These findings suggest that highly
plastic prostate cancer cells utilize alternative mechanisms to eventually escape drug
treatments that target AR.
METABOLISM OF ANDROSTANEDIOL TO DHT
The classical pathway for DHT synthesis is conversion in the testis of the major adrenal
androgen androstenedione to T, followed by irreversible 5α-reduction of T to DHT by 5α-
reductase type 2 in prostate and other, but not all, androgen target tissues (Fig. 1) (29).
Studies in the beagle dog (30) and tammar wallaby (31, 32) indicate an alternative backdoor
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pathway of DHT synthesis that utilizes androstanediol as precursor instead of T.
Androstanediol is the major degradation product of DHT from the reductive 3α-
hydroxysteroid dehydrogenase (HSD) activity of 3α-HSD aldo-keto reductases 1C
(AKR1C) (Fig. 1), enzymes with both 3- and 17-ketosteroid reductase activity (33–38). AR
binds androstanediol with moderate affinity, but androstanediol must be converted to DHT
to induce transactivation by wild-type AR. Enzymes that convert androstanediol to DHT
include 17β-hydroxysteroid dehydrogenase 6 (17β-HSD6 or HSD17B6, known also as
retinol dehydrogenase (RODH) 3α-HSD) (39), 17β-hydroxysteroid dehydrogenase 10 (17β-
HSD10 or HSD17B10) (40), retinol dehydrogenase 5 (RDH5) (39), dehydrogenase/
reductase short-chain dehydrogenase/reductase family member 9 (DHRS9) (33, 41) and
retinol dehydrogenase 4 (RODH4) (42).
Recent studies suggest that benign human prostate and prostate cancer cells express
predominantly 17β-HSD6 as the major enzyme that converts androstanediol to DHT, and it
is DHT that accounts for AR transactivation in the presence of androstanediol (43). Precise
measurements of relative enzyme activity of several hydroxysteroid dehydrogenases active
in this reaction are complicated by the requirement for optimal pH and nicotinamide adenine
dinucleotide cofactors. However, 17β-HSD6 mRNA levels determined using RT-PCR and
protein levels on immunoblots suggest a direct link between 17β-HSD6 expression,
bioconversion of androstanediol to DHT, and AR activation in the presence of
androstanediol.
Androstanediol is not a major adrenal androgen. Thus, to serve as a significant intracellular
precursor for DHT synthesis, androstanediol must be synthesized from steroid precursors
earlier in the biosynthetic pathway. The backdoor pathway of DHT biosynthesis in benign
prostate and prostate cancer cells depends on intracellular 5α-reductase type 1 and 2
isoforms, and the conversion of androsterone to androstanediol or androstanedione (Fig. 1).
In both pathways, 17α-hydroxyprogesterone serves as a principal intermediate independent
of DHEA, androstenedione or T. Progesterone and 17α-hydroxyprogesterone were shown to
be excellent substrates for 5α-reductase type 1 and 2 (8, 44) that form dihydroprogesterone
and 17α-hydroxydihydroprogesterone, respectively (Fig. 1). 5α-reductase type 1
predominates in this reaction, and expression of 5α-reductase type 1 increases during
prostate cancer progression (45, 46) and possibly in prostate cancer tissue during androgen
deprivation therapy (47). A recently described ubiquitously expressed 5α-reductase type 3
isoform is present at higher levels in prostate cancer (48, 49). Although 17α-
hydroxyprogesterone is not considered an important sex steroid precursor in normal human
physiology (8), increased levels of 5α-reductase types 1 and 3 may facilitate conversion in
this pathway that culminates in the formation of DHT.
Continuing in this pathway, reductive 3αHSD converts 17α-hydroxydihydroprogesterone to
17α-hydroxyallopregnanolone (Fig. 1). 17α-hydroxylase/17,20 lyase (P450c17) acts on 17α-
hydroxyallopregnanolone to form androsterone. Once androsterone is formed, two possible
pathways involve 17β-HSD6 to catalyze the formation of DHT. 17β-HSD6 converts
androsterone to androstanedione, which is converted to DHT by 17βHSD3. Androsterone is
converted to androstanediol by 17βHSD3 (50), and androstanediol is converted to DHT by
17β-HSD6. The complementary DNA for 17β-HSD6 was originally cloned from prostate
(39). 17β-HSD6 is central to the backdoor pathway of DHT synthesis independent of
circulating T, appears to be a critical enzyme in prostate cancer cells, and is a potential drug
target for treating prostate cancer.
Mohler et al. Page 3














Accumulating evidence that intratumoral androgen production drives prostate cancer growth
by activating AR has driven efforts to identify new drugs that target enzymes responsible for
androgen biosynthesis. Clinical trials using the 5α-reductase inhibitors finasteride and
dutasteride have achieved success in the treatment of benign prostate enlargement but less so
for prostate cancer. Critical evaluation of new opportunities to interrupt androgen
metabolism has been difficult for several reasons. Steroid metabolic enzymes often exist as
multiple isozymes, enzyme function cannot be predicted based on enzyme protein or mRNA
levels alone, and in vitro assay conditions may differ from the microenvironment of prostate
cancer cells. Enzymes, substrates and products may be at low levels and enzymatic action
may differ among tissue compartments so that whole tissue assays are misleading. In
addition, fundamental knowledge gaps exist in androgen transport across membranes, such
as how androgens transit the vascular endothelium.
The human CYP17A1 gene codes for P450c17, an enzyme with dual functions in the
intracrine metabolism of testosterone and DHT from progesterone via the cholesterol
pathway (Fig. 1). 17α-hydroxylase and 17,20-lyase activities of P450c17 act on
pregnenolone and progesterone precursors to produce DHT via 5α-pregnane-3α,17α-diol-20-
one through the backdoor pathway. Ketoconazole is a nonspecific weak inhibitor of
P450c17 with limited antitumor properties and excessive toxicity. Recent appreciation of
intracrine metabolism of active androgens from adrenal precursors, and the efficacy but high
toxicity of ketoconazole led Attard, deBono and colleagues to search for a “better
ketoconazole.”
Abiraterone acetate is an irreversible inhibitor of the 17α-hydroxylase and lyase activities of
P450c17 (51). Abiraterone acetate suppresses 17α-hydroxylation of pregnenolone and
progesterone, and the 17,20-lyase activity of P450c17 that converts 17α-
hydroxypregnenolone to DHEA, and 17α-hydroxyprogesterone to androstenedione (Fig. 1)
(8). Because 17α-hydroxyprogesterone is a precursor of androsterone and androstanediol,
abiraterone acetate would be expected to inhibit the backdoor pathway of DHT synthesis.
Although serum androgen, estrogen and PSA levels were suppressed by abiraterone acetate,
overall effects were often transient, and prolonged use was associated with a compensatory
increase in ACTH and mineralocorticoid excess (52). The duration of response to
abiraterone acetate monotherapy and abiraterone-corticosteroid combination therapy ranges
from 9 to 14 months, with the response associated with high levels of adrenal androgens
prior to initiation of therapy (53). These findings were consistent with a report that higher
circulating adrenal androgen was associated with longer survival in men with CRPC (54).
Failure to achieve long term benefit from 5α-reductase or P450c17 inhibitors in the
treatment of prostate cancer may result from incomplete enzyme inhibition, a compensatory
rise in intratumoral T, alternative pathways of DHT synthesis, or increased AR sensitivity to
low androgen in association with increased levels of AR coregulators and AR
phosphorylation (55, 56). When androstanediol was provided as substrate, 17β-HSD6 was
the major enzyme that converted androstanediol to DHT in normal human prostate and
prostate cancer cells. Enzymatic conversion of androstanediol to DHT represents a new
potential drug target to block prostate cancer progression that raises several questions. First,
the extent to which 17β-HSD6 is responsible for androstanediol conversion to DHT in
prostate cells remains unclear. Other enzymes such as DHRS9 and RDH5 may be active. In
support of 17β-HSD6 as a drug target, AR transactivation in the presence of androstanediol
correlated directly with 17β-HSD6 mRNA and protein in different cell types. However, 17β-
HSD6 mRNA levels declined with time after castration in the androgen-dependent CWR22
human prostate cancer xenograft model and in human specimens, whereas DHRS9 and
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RDH5 mRNA levels were relatively unchanged after castration. 17β-HSD6 could maintain
DHT levels sufficient to activate AR, or rely on the activity of other enzymes. A key to
defining 17β-HSD6 as a drug target in the treatment of prostate cancer will be to establish
the relative contribution of other enzymes that maintain AR activation by androgen
precursors.
A second consideration is the redundancy of androgen biosynthetic pathways that suggests
prostate cancer cells deprived of testicular androgens recruit multiple mechanisms for the
intracrine synthesis of DHT, the most potent naturally occurring AR ligand. A greater
clinical response may be achieved through the use of inhibitors directed at different points
along the pathway, with a longer lasting clinical response in advanced prostate cancer when
a putative 17β-HSD6 inhibitor is combined with the dual 5α-reductase inhibitor dutasteride,
LHRH agonist or AR antagonist. Such a multi-pronged approach could provide greater
clinical benefit when administered earlier in the course of disease progression prior to the
onset of CRPC.
Recent evidence has suggested the existence of constitutively active AR splice variants that
lack the ligand binding domain and contribute to prostate cancer progression independent of
intratumoral androgen (57–60). However, AR is highly susceptible to degradation in the low
androgen environment of prostate cancer cells, such that partial AR degradation could
account for some reported smaller forms (61). Although higher levels of AR splice variants
were reported in certain prostate cancer cell lines (58) that are often subject to complex
chromosome abnormalities, AR variants were in much lower abundance in prostate cancer
specimens relative to full-length AR (57, 60). Overall the findings support the potential
clinical usefulness of drugs that target androgen biosynthesis to achieve temporary reduction
in tumor growth.
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Figure 1. Backdoor pathway of DHT synthesis involves the conversion of androstanediol to DHT
by 17β-HSD6
Conversion of cholesterol to prenenolone by the P450 side chain cleavage enzyme (P450ssc)
is the first committed step in steroid biosynthesis. The 17α-hydroxylase/17,20-lyase
(P450c17) catalyzes multiple 17α-hydroxylase and 17,20-lyase reactions in the
steroidogenic pathway that require P450 oxidoreductase (P450ox/red) electron transfer.
P450c17 coded by the CYP17A1 gene is the target for inhibition by abiraterone acetate.
Progesterone, 17α-hydroxyprogesterone (17α-OH-progesterone) and testosterone are
substrates for 5α-reductase type 1, 2 or 3 (5αR1, 2 or 3). Finasteride is an 5αR2 inhibitor.
Dutasteride is an inhibitor of 5αR1, 5αR2 and 5αR3. Isozymes of 3β-hydroxysteroid
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dehydrogenase (3βHSD), 17β-hydroxysteroid dehydrogenase (17βHSD) and aldo-keto
reductase (AKR1C3) are often reversible enzymes with oxidative and reductive activities
that require nicotinamide adenine dinucleotide cofactors. Testosterone and DHT are the two
biologically active androgens that activate AR. Testosterone is the major circulating active
androgen formed in the testis. DHT is formed from testosterone in the testis, and can be
synthesized in a so-called backdoor pathway (green) from progesterone and androsterone
precursors independent of DHEA, androstenedione or testosterone intermediates.
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